TSHA
Taysha Gene Therapies Inc
NASDAQ: TSHA · HEALTHCARE · BIOTECHNOLOGY
$6.27
-0.48% today
Updated 2026-04-29
Market cap
$1.80B
P/E ratio
—
P/S ratio
184.35x
EPS (TTM)
$-0.34
Dividend yield
—
52W range
$2 – $7
Volume
2.9M
Taysha Gene Therapies Inc (TSHA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $2.50M | $15.45M | $8.33M | $9.77M |
| Revenue growth (YoY) | — | — | — | — | +517.5% | -46.1% | +17.3% |
| Cost of revenue | — | $9000.00 | $492000.00 | $2.49M | $1.37M | $1.25M | $1.15M |
| Gross profit | — | $-9000.00 | $-492000.00 | $14999.00 | $15.45M | $8.33M | $8.63M |
| Gross margin | — | — | — | 0.6% | 100.0% | 100.0% | 88.3% |
| R&D | $987000.00 | $31.89M | $131.94M | $91.17M | $56.78M | $66.00M | $86.40M |
| SG&A | $512000.00 | $11.10M | $41.32M | $37.36M | $30.05M | $28.95M | $33.87M |
| Operating income | $-1.11M | $-43.00M | $-173.27M | $-126.03M | $-72.44M | $-91.46M | $-110.50M |
| Operating margin | — | — | — | -5037.1% | -468.8% | -1097.6% | -1130.6% |
| EBITDA | $-1.11M | $-59.97M | $-172.60M | $-159.73M | $-105.20M | $-87.95M | $-109.35M |
| EBITDA margin | — | — | — | -6384.1% | -680.8% | -1055.5% | -1118.9% |
| EBIT | $-5.58M | $-59.98M | $-173.09M | $-162.22M | $-106.57M | $-89.20M | $-110.50M |
| Interest expense | $0.00 | $28000.00 | $1.43M | $3.80M | $5.00M | $102000.00 | $63000.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1.11M | $-43.00M | $-174.52M | $-166.01M | $-111.57M | $-89.30M | $-109.00M |
| Net income growth (YoY) | — | -3756.5% | -305.9% | +4.9% | +32.8% | +20.0% | -22.1% |
| Profit margin | — | — | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |